Mtz Clinical Research Powered By Pratia

The Clinical Unit at Mtz Clinical Research Powered By Pratia is conducting studies focused on disorders of the nervous system, aiming to test innovative treatments that improve neurological function and quality of life.

• Early Alzheimer's disease with inflammatory biomarkers
• Refractory focal onset epilepsy
• Relapsing‑remitting multiple sclerosis
• Agitation associated with dementia

Across 81 trials, 52 investigators are exploring disease‑modifying approaches for these conditions, offering patients access to cutting‑edge therapeutic options.

Research at the site spans solid tumors and blood cancers, evaluating novel agents that target tumor growth and improve survival outcomes.

• Advanced hepatocellular carcinoma with FGFR2b overexpression
• Relapsed or refractory B‑cell malignancies
• Higher‑risk myelodysplastic syndromes
• Paroxysmal nocturnal hemoglobinuria

The program includes combination regimens and immunotherapy strategies, reflecting a commitment to advancing cancer care in Warsaw.

The facility is engaged in trials that assess cardiovascular risk reduction and metabolic disease management, testing therapies that aim to lower events and improve metabolic parameters.

• High‑risk patients without prior myocardial infarction or stroke
• Resistant hypertension resistant to multiple drug classes
• Metabolic dysfunction‑associated steatohepatitis (MASH) with fibrosis
• Type 2 diabetes and related complications

With a strong focus on heart failure and lipid‑lowering agents, the trials support personalized cardiovascular therapy for diverse patient populations.

Studies at the Warsaw site target conditions driven by immune dysregulation, evaluating biologics and small molecules that modulate immune pathways.

• Generalized myasthenia gravis
• Moderate‑to‑severe atopic dermatitis
• Primary Sjögren’s syndrome
• Warm autoimmune hemolytic anemia

The trials aim to reduce disease activity and improve patient‑reported outcomes, positioning the center as a hub for immune‑targeted research.

The clinical program includes investigations of new agents for chronic inflammatory skin conditions, seeking to achieve faster symptom relief and long‑term disease control.

• Plaque psoriasis with moderate to severe involvement
• Psoriatic arthritis
• Chronic atopic dermatitis
• Linear IgA dermatosis

By testing targeted inhibitors and biologics, the site contributes to expanding therapeutic choices for patients with difficult‑to‑treat skin diseases.

Research efforts encompass viral infections and respiratory conditions, focusing on preventive vaccines and antiviral therapies to reduce disease burden.

• Respiratory syncytial virus (RSV) in adults over 60
• Human metapneumovirus
• Recurrent vulvovaginal candidiasis
• Varicella infection

These studies aim to enhance immunity and provide effective treatment options for both acute and chronic respiratory infections.

The site’s psychiatric portfolio investigates novel interventions for mood and anxiety disorders, targeting symptom reduction and relapse prevention.

• Major depressive disorder with anhedonia
• Insomnia disorder
• Agitation in early Alzheimer's disease
• Relapse prevention in depression using adjunctive agents

By integrating pharmacologic and behavioral endpoints, the trials support a holistic approach to mental health care.